Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood. 2008 May 1;111(9):4463-70. doi: 10.1182/blood-2007-08-105759. Epub 2008 Feb 21.

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.

Collaborators (162)

Abdalsamad I, Dagger MF, Allard C, Angonin R, d'Anjou J, Audhuy B, Audouin J, Auzanneau G, Baglin AC, Bacilli C, Bastion Y, Baumelou E, Bensimon P, Berger F, Biron P, Blaise AM, Blanc M, Boman-Ferrand F, Boehn A, Boniver J, Bordes M, Bordessoule D, Bosly A, Bosq J, Bouabdallah R, Boucheron S, Bouvier J, Brice P, Brière J, Brousse N, Brousset P, Bryon PA, Caillot D, Carbillet JP, Casasnovas RO, Caulet T, Cazals D, Charlotte F, Charvillat L, Chesneau AM, Christian B, Coiffier B, Conroy T, Cordier JF, Cordonnier C, Clauvel JP, Deconinck E, Delage M, Delannoy A, Delmer A, Delos M, Delsol G, Devidas A, Diebold J, Diviné M, Dombret H, Doyen C, Duplay H, Dupriez B, Duval C, Eisenmann JC, Elbaz D, Emberger JM, Epardeau B, Fabiani B, Felman P, Fermand JP, Fermé C, Ferrand A, Ffrench M, Fievez M, Fillet G, Fonck Y, Froment N, Gabarre J, Galian P, Gasser O, Gaulard P, Gisselbrecht C, Gosselin B, Goutier C, Guy H, Guyotat D, Haioun C, Hamels J, Herbrecht R, Hopfner O, Horschowski N, Huguet F, Jacomy P, Jaubert J, Jeandel R, Kerneis Y, Knopf JP, Kuentz M, Labouyrie E, Lancien B, Laurent G, Lavergne A, Lavignac C, Leblond V, Lecomte-Houke M, Léderlin P, Lejeune F, Leger-Ravet MB, Loire R, Marcellin R, Marolleau JP, Marit G, Martin C, Marty-Double C, De Mascarel A, Méhaut S, Merlio JP, Merignargues C, Micléa JM, Michaux JL, Molina T, Monconduit M, Morel P, Morvan F, Mosnier JF, Nédellec G, Netter-Pinon C, Noel H, Nouvel C, Patey M, Peaud PY, Perie G, Peuchmaur M, Petrella T, Pignon B, Platini C, Pluot M, Pollet JP, Pujade-Lauraine E, Raphael M, Raymond-Gelle MC, Reiffers J, Reyes F, Rochet M, Rossi JF, Roucayrol AM, Rozenbaum A, Salles G, Schill H, Sebban C, Simon M, Solal-Céligny P, Straub P, Suc E, Sutton L, Symann M, Tertian G, Thiebaut S, Thyss A, Tilly H, Travade P, Trillet V, Vernant JP, Wendum D, Xerri L.

Author information

1
Inserm U728, Paris, France.

Abstract

To evaluate the prognostic significance of clinicobiologic and pathological features in angioimmunoblastic T-cell lymphoma (AITL), 157 AITL patients were retrieved from the GELA LNH87-LNH93 randomized clinical trials. One hundred forty-seven patients received a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like regimen with intensified courses in half of them. Histologically, 41 cases were classified as "rich in large cells" and 116 as "classic" (including 19 rich in epithelioid cells, 14 rich in clear cells, and 4 with hyperplastic germinal centers). Sixty-two cases were scored for CD10 and CXCL13 expression according to the abundance of positive lymphoid cells. Median age was 62 years, with 81% advanced stage, 72% B symptoms, 65% anemia, 50% hypergammaglobulinemia, and 66% elevated LDH. Overall 7-year survival was 30%. In multivariate analysis, only male sex (P = .004), mediastinal lymphadenopathy (P = .041), and anemia (P = .042) adversely affected overall survival. Increase in large cells and high level of CD10 and CXCL13 did not affect survival. Intensive regimen did not improve survival. In conclusion, AITL is a morphologically heterogeneous T-cell lymphoma commonly expressing CXCL13 and CD10 and carrying few prognostic factors. It portends a poor prognosis even when treated intensively. However, AITL is not always lethal with 30% of patients alive at 7 years.

PMID:
18292286
PMCID:
PMC2343588
DOI:
10.1182/blood-2007-08-105759
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center